CDTX News and Press, Cidara Therapeutics Inc. From 03/02/23

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten public offer...

Cidara Therapeutics ( NASDAQ: CDTX ) closed up 31% on Wednesday, boosted by positive interim results from a mid-stage trial on CD388, its prophylactic drug candidate for influenza. Results on healthy volunteers showed that CD388 decreased influenza viral replication in the upper...

Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...

If you’re making a list of penny stocks to buy, you have plenty to choose from. In the stock market today, volatility has created a higher-risk environment to trade in. With that, those well-versed in stocks that perform well during times like these have benefited. Penny stocks are...

Cidara Therapeutics ( NASDAQ: CDTX ) said interim data from an ongoing Phase 2a trial showed that a single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model compared to placebo. The s...

A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model when compared to placebo CD388 was generally safe and well tolerated with no adverse events related to study drug reported as of th...

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it will present highlights from pharmacokinet...

Summary Cidara Therapeutics is a biotechnology company developing rezafungin, a long-acting echinocandin antifungal drug, for the treatment of invasive candidiasis and candidemia. Rezafungin showed non-inferiority to caspofungin and could be an alternative to standard-of-care, but its m...

Biotechnology company Cidara Therapeutics ( NASDAQ: CDTX ) said it has received a Nasdaq notice on having regained compliance with the stock exchange's minimum bid price requirement. Nasdaq had first notified the company on Feb. 28, 2022, that its shares had failed to maintain a ...

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq...